James Wild
Family Medicine · Gowanda, NYNPI 1437140985
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Shionogi Inc at 59.2% of the total. Reporting peaked in 2019 at $6,641 and has fallen 87.3% since, to $845 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 494 payments — averaging $39.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$11K
- Lilly USA, LLC$1K
- Novo Nordisk$813
- Novartis$597
- Amgen$595
- GSK$430
- plus $4K from 33 others
Across 285 payments — averaging $7861.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$695K
- AbbVie$668K
- Pfizer$347K
- Acella Pharmaceuticals, LLC$171K
- Lexicon Pharmaceuticals, Inc.$81K
- Anika Therapeutics, Inc.$38K
- plus $240K from 11 others
What the payments were for
- Speaking & faculty fees$11,49659%
- Food & beverage$7,82740%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,404 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $154,608 |
| OzempicSemaglutide | 62 | $73,441 |
| FarxigaDapagliflozin Propanediol | 62 | $67,028 |
| JardianceEmpagliflozin | 70 | $64,154 |
| XareltoRivaroxaban | 46 | $57,555 |
| RybelsusSemaglutide | 42 | $46,883 |
| TrulicityDulaglutide | 40 | $42,969 |
| MyrbetriqMirabegron | 47 | $29,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,336 |
| MounjaroTirzepatide | 20 | $21,322 |
| SavellaMilnacipran Hcl | 29 | $17,309 |
| EntrestoSacubitril/Valsartan | 14 | $15,670 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $15,274 |
| JanuviaSitagliptin Phosphate | 16 | $13,616 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $8,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $404 | $154,608192 claims |
| Novo NordiskOzempic, Rybelsus | $813 | $120,324104 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $387 | $79,91092 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,352 | $64,29160 claims |
| Boehringer IngelheimJardiance | $226 | $64,15470 claims |
| Johnson & JohnsonXarelto | $349 | $57,55546 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $430 | $51,21874 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $282 | $36,69160 claims |
| MerckJanuvia, Belsomra | $181 | $19,68430 claims |
| AbbVieSavella | $405 | $17,30929 claims |
| NovartisEntresto | $597 | $15,67014 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $246 | $7,18011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Gowanda
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.